Regulus Therapeutics Inc. – NASDAQ:RGLS
Regulus Therapeutics stock price today
$8.05
+6.51
+422.73%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Regulus Therapeutics stock price monthly change
-9.94%
month
Regulus Therapeutics stock price quarterly change
-9.94%
quarter
Regulus Therapeutics stock price yearly change
+17.56%
year
Regulus Therapeutics key metrics
Market Cap | 100.20M |
Enterprise value | N/A |
P/E | -0.53 |
EV/Sales | N/A |
EV/EBITDA | 0.07 |
Price/Sales | N/A |
Price/Book | 0.44 |
PEG ratio | -0.01 |
EPS | -1.46 |
Revenue | N/A |
EBITDA | -31.97M |
Income | -31.36M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRegulus Therapeutics stock price history
Regulus Therapeutics stock forecast
Regulus Therapeutics financial statements
| Jun 2023 | 0 | -7.01M | |
|---|---|---|---|
| Sep 2023 | 0 | -7.82M | |
| Dec 2023 | 302K | -8.06M | -2669.21% |
| Mar 2024 | 0 | -8.46M |
| Sep 2025 | 0 | -3.23M | |
|---|---|---|---|
| Oct 2025 | 0 | -5.60M | |
| Dec 2025 | 0 | -3.95M | |
| Dec 2025 | 0 | -5.60M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 43647000 | 9.65M | 22.11% |
|---|---|---|---|
| Sep 2023 | 37747000 | 9.48M | 25.14% |
| Dec 2023 | 30750000 | 9.56M | 31.1% |
| Mar 2024 | 114138000 | 6.55M | 5.74% |
| Jun 2023 | -6.25M | 0 | 13.20M |
|---|---|---|---|
| Sep 2023 | -6.27M | -5.44M | 287K |
| Dec 2023 | -6.12M | 4.93M | -873K |
| Mar 2024 | -8.74M | -78.54M | 93.10M |
Regulus Therapeutics alternative data
| Aug 2023 | 31 |
|---|---|
| Sep 2023 | 30 |
| Oct 2023 | 30 |
| Nov 2023 | 30 |
| Dec 2023 | 29 |
| Jan 2024 | 29 |
| Feb 2024 | 29 |
| Mar 2024 | 30 |
| Apr 2024 | 30 |
| May 2024 | 30 |
| Jun 2024 | 30 |
| Jul 2024 | 28 |
Regulus Therapeutics other data
35.50%
-18.72%
of RGLS is owned by hedge funds
5.41M
-2.69M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 25516 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CALSADA CRISPINA officer: Chief Financial Officer | Common Stock | 5,468 | $1.19 | $6,512 | ||
Sale | AKER CHRISTOPHER RAY officer: Sr. VP &.. | Common Stock | 5,468 | $1.19 | $6,512 | ||
Sale | HAGAN JOSEPH P director, officer: Chief Execut.. | Common Stock | 14,580 | $1.19 | $17,365 | ||
Purchase | DRYGIN DENIS officer: Chief Scientific Officer | Common Stock | 76,686 | $0.23 | $17,638 | ||
Purchase | DRYGIN DENIS officer: Chief Scientific Officer | Common Stock | 23,314 | $0.23 | $5,362 | ||
Purchase | HAGAN JOSEPH P director, officer: President an.. | Common Stock | 100,000 | $0.22 | $21,500 | ||
Sale | AKER CHRISTOPHER RAY officer: Sr. VP &.. | Common Stock | 860 | $0.89 | $765 | ||
Sale | HAGAN JOSEPH P director, officer: President an.. | Common Stock | 4,186 | $0.89 | $3,726 | ||
Sale | HAGAN JOSEPH P director, officer: President an.. | Common Stock | 8,288 | $0.86 | $7,128 | ||
Sale | AKER CHRISTOPHER RAY officer: Sr. VP &.. | Common Stock | 828 | $1.72 | $1,424 |
| Patent |
|---|
Application Filling date: 21 Mar 2022 Issue date: 7 Jul 2022 |
Application Filling date: 12 Nov 2019 Issue date: 31 Mar 2022 |
Application Filling date: 19 Jul 2019 Issue date: 31 Mar 2022 |
Application Filling date: 5 Oct 2021 Issue date: 27 Jan 2022 |
Application Galnac Conjugated Modified Oligonucleotides as MIR-122 Inhibitor Having HCV Antiviral Activity with Reduced Hyperbilirubinemia Side-Effect Filling date: 7 May 2019 Issue date: 10 Jun 2021 |
Application Filling date: 16 Oct 2020 Issue date: 15 Apr 2021 |
Application Filling date: 25 Sep 2020 Issue date: 1 Apr 2021 |
Grant Filling date: 17 Jan 2019 Issue date: 9 Mar 2021 |
Application Filling date: 27 Aug 2020 Issue date: 17 Dec 2020 |
Application Filling date: 27 Aug 2020 Issue date: 17 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2022 10 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 10 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Joseph P. Hagan M.B.A. (1969) Pres, Chief Executive Officer & Director | $826,080 |
| Mr. Christopher Ray Aker J.D. (1961) Senior Vice President, Gen. Counsel & Corporation Sec. | $457,470 |
-
What's the price of Regulus Therapeutics stock today?
One share of Regulus Therapeutics stock can currently be purchased for approximately $8.05.
-
When is Regulus Therapeutics's next earnings date?
Unfortunately, Regulus Therapeutics's (RGLS) next earnings date is currently unknown.
-
Does Regulus Therapeutics pay dividends?
No, Regulus Therapeutics does not pay dividends.
-
How much money does Regulus Therapeutics make?
Regulus Therapeutics has a market capitalization of 100.20M.
-
What is Regulus Therapeutics's stock symbol?
Regulus Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "RGLS".
-
What is Regulus Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Regulus Therapeutics?
Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Regulus Therapeutics's key executives?
Regulus Therapeutics's management team includes the following people:
- Mr. Joseph P. Hagan M.B.A. Pres, Chief Executive Officer & Director(age: 56, pay: $826,080)
- Mr. Christopher Ray Aker J.D. Senior Vice President, Gen. Counsel & Corporation Sec.(age: 64, pay: $457,470)
-
How many employees does Regulus Therapeutics have?
As Jul 2024, Regulus Therapeutics employs 28 workers, which is 7% less then previous month and 7% less then previous quarter.
-
When Regulus Therapeutics went public?
Regulus Therapeutics Inc. is publicly traded company for more then 12 years since IPO on 9 Oct 2012.
-
What is Regulus Therapeutics's official website?
The official website for Regulus Therapeutics is regulusrx.com.
-
Where are Regulus Therapeutics's headquarters?
Regulus Therapeutics is headquartered at 4224 Campus Point Court, San Diego, CA.
-
How can i contact Regulus Therapeutics?
Regulus Therapeutics's mailing address is 4224 Campus Point Court, San Diego, CA and company can be reached via phone at 858 202 6300.
Regulus Therapeutics company profile:
Regulus Therapeutics Inc.
regulusrx.comExchange:
NASDAQ
Full time employees:
32
Industry:
Biotechnology
Sector:
Healthcare
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
4224 Campus Point Court
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001505512
ISIN: US75915K3095
CUSIP: 75915K309
